Spinogenix Reports Positive Data on Alzheimer's Patients Who Continued Treatment With Tazbentetol For Up To 84 Weeks

Tazbentetol, a First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Demonstrated Favorable Safety Profile and Durable Therapeutic Benefits Clinical Case Study Presented at AAIC Highlights Caregiver Report of Rapid Cognitive Improvement with Supporting Clinical Outcome...